Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Appointed director
|
|
Fortress Biotech, Inc. (FBIO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Quarterly results |
| 09/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 09/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 09/27/2023 |
4
| ROSENWALD LINDSAY A MD (President, CEO & Chairman) has filed a Form 4 on Fortress Biotech, Inc.|
Txns:
| Bought 100,000 shares
@ $0.2833, valued at
$28.3k
|
|
| 09/26/2023 |
SC 13D/A
| Fortress Biotech, Inc. reports a 11.3% stake in CHECKPOINT THERAPEUTICS, INC. |
| 09/26/2023 |
4
| Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 80,906 shares
@ $0 |
|
| 08/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/21/2023 |
4
| ROSENWALD LINDSAY A MD (President, CEO & Chairman) has filed a Form 4 on Fortress Biotech, Inc.|
Txns:
| Bought 10,000 shares
@ $11.75, valued at
$117.5k
Bought 10,000 shares
@ $9.34, valued at
$93.4k
|
|
| 08/15/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
SC 13D/A
| Fortress Biotech, Inc. reports a 13.6% stake in CHECKPOINT THERAPEUTICS, INC. |
| 07/03/2023 |
4
| Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 81,406 shares
@ $0 |
|
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex... |
| 05/26/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 04/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/14/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/13/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/04/2023 |
4
| Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 52,419 shares
@ $0 |
|
| 04/04/2023 |
4
| Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 35,714 shares
@ $0
Granted 42,500 shares
@ $0 |
|
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/14/2023 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 7.3% stake in FORTRESS BIOTECH, INC. |
| 02/14/2023 |
4
| ROSENWALD LINDSAY A MD (President, CEO & Chairman) has filed a Form 4 on Fortress Biotech, Inc.|
Txns:
| Bought 2,395,209 shares
@ $0.835, valued at
$2M
|
|
| 02/14/2023 |
4
| LOBELL J JAY (Director) has filed a Form 4 on Fortress Biotech, Inc.|
Txns:
| Bought 299,401 shares
@ $0.835, valued at
$250k
|
|
| 02/14/2023 |
4
| Jin David (CFO) has filed a Form 4 on Fortress Biotech, Inc.|
Txns:
| Bought 35,928 shares
@ $0.835, valued at
$30k
|
|
| 02/10/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 02/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 4.7% stake in Fortress Biotech Inc |
| 01/13/2023 |
SC 13D/A
| Fortress Biotech, Inc. reports a 20.7% stake in MUSTANG BIO, INC. |
|
|
|